Join CODE. Join the Oncology Data Network

CODE connects the European cancer community with its data in new and powerful ways

A Collaboration shining new light on Europe’s anti-cancer medicines use

Join the Collaboration helping Europe’s oncology community understand anti-cancer medicines use in practice

An up-to-date intelligence source for the European oncology community

CODE aims to connect information on anti-cancer medicine use for all cancers, all patients, across all treatment centres in Europe who wish to join

Permitting new models of access, championing treatment choice

CODE aims to enable the oncology community to derive greater value from anti-cancer medicines for patients

Join CODE. Join the Oncology Data Network

CODE connects the European cancer community with its data in new and powerful ways

A Collaboration shining new light on Europe’s anti-cancer medicines use

Join the Collaboration helping Europe’s oncology community understand anti-cancer medicines use in practice

An up-to-date intelligence source for the European oncology community

CODE aims to connect information on anti-cancer medicine use for all cancers, all patients, across all treatment centres in Europe who wish to join

Permitting new models of access, championing treatment choice

CODE aims to enable the oncology community to derive greater value from anti-cancer medicines for patients

Why CODE matters

There is an enormous effort driving innovation in anti-cancer medicines, yet surprisingly little is known about how different drugs are being used in clinical practice today.

The Collaboration for Oncology Data in Europe (CODE) aims to expand our knowledge of anti-cancer medicines use by supporting the development of a dedicated Oncology Data Network. The data collated will enable the oncology community to derive greater value from anti-cancer medicines for patients.

The Collaboration for Oncology Data in Europe (CODE) is supporting the creation of a large-scale Oncology Data Network that will collate comprehensive, up-to-date data to describe how anti-cancer medicines are actually used in clinical practice. The technology platform has been designed to be able to aggregate data on anti-cancer medicine usage for all forms of cancer, in all patients and for all treatment centres across Europe who wish to join.

The aim is to collaborate with 200 cancer treatment centres in seven European countries in the first three years, scaling potentially to an estimated 2,000 treatment centres across Europe over 10 years.

For the first time, treatment centres joining the Oncology Data Network will be able to explore near real-time, clinically robust, real-world information that will describe how anti-cancer medicines are being used in today’s clinical practice, for which patients groups, and in which combinations and sequences, across Europe.

The members of CODE believe that creating this Oncology Data Network will pave the way for the European oncology community to increase its understanding of today’s clinical practice. Only by understanding how anti-cancer medicines are used will we create the necessary foundation for new approaches to access of innovative therapies, helping to connect treatment innovation to patient benefit and broaden the opportunity for individual patients to receive the therapies that are appropriate for them.

Treatment centres join the Oncology Data Network by agreeing to contribute their data on the use of anti-cancer medicines in their centre

3 Protection

Ensure high standards of privacy and data protection, information governance and security. All data contributed pass through a highly-secure, multi-stage process to be rendered non-identifiable and are aggregated before analyses are released

4 Centre information

Treatment centres that are part of the Oncology Data Network receive the tools for near real-time analysis via the platform to understand their own data and practices

5 Network information

CODE’s Founding Members, members of the Oncology Data Network and members of the wider oncology community (on request), are able to access aggregated analyses once the data have passed through a highly-secure, multi-stage process to be rendered non-identifiable

6 Ongoing engagement

Continue to engage with clinicians and decision makers to help treatment centres maximise the value of their involvement with the Oncology Data Network and CODE

The Collaboration

The challenges of cancer data, and the nature of clinical practice in oncology, are so complex that a collaborative approach is vital. That’s why CODE has been established: to focus on an issue that touches multiple different stakeholders by facilitating contributions from healthcare professionals, professional societies, national agencies, governments and patient groups. This is how CODE will remain relevant and meet the needs of patients, physicians, treatment centres and the whole oncology community.